NCT/Study#

NCT03918278 /

MK-0482-001

A Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-0482 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.

A Phase 1b, open-label, dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MK-0482 as monotherapy and in combination with pembrolizumab in participants with advanced/metastatic solid tumors.

DISEASE GROUP:
Phase 1
current phase:
Phase I
STUDY STATUS:
Accepting Patients
Location:
Hackensack, NJ
For More information: